| (19) |
 |
|
(11) |
EP 1 439 220 B1 |
| (12) |
EUROPEAN PATENT SPECIFICATION |
| (45) |
Mention of the grant of the patent: |
|
22.08.2007 Bulletin 2007/34 |
| (22) |
Date of filing: 16.01.2003 |
|
| (51) |
International Patent Classification (IPC):
|
|
| (54) |
Immobilized biocatalysts usable for the manufacture of natural nucleosides and modified
analogues through enzymatic transglycosylation reactions
Immobilisierte Biokatalysatoren für die Herstellung von natürlichen Nukleosiden und
modifizierten Analogen durch enzymatische Transglykosylierungsreaktionen
Biocatalyseurs immobilisés pour la production des nucléosides naturels et des analogues
modifiés par des réactions enzymatiques de transglycolysation
|
| (84) |
Designated Contracting States: |
|
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT SE SI SK TR |
| (43) |
Date of publication of application: |
|
21.07.2004 Bulletin 2004/30 |
| (73) |
Proprietor: Adorkem Technology SpA |
|
24062 Costa Volpino (Bergamo) (IT) |
|
| (72) |
Inventors: |
|
- Tonon, Giancarlo
20139 Milano (IT)
- Capra, Emanuele
26900 Lodi (IT)
- Orsini, Gaetano
21013 Gallarate (Varese) (IT)
- Zuffi, Gabriele
20026 Novate Milanese (Milano) (IT)
|
| (74) |
Representative: Pistolesi, Roberto et al |
|
Dragotti & Associati srl
Via Turati 32 20121 Milano 20121 Milano (IT) |
| (56) |
References cited: :
EP-A- 0 346 865 WO-A-03/008619
|
EP-A- 0 897 014 US-A- 5 314 810
|
|
| |
|
|
- MAHMOUDIAN M: "BIOCATALYTIC PRODUCTION OF CHIRAL PHARMACEUTICAL INTERMEDIATES" BIOCATALYSIS
AND BIOTRANSFORMATION, HARWOOD ACADEMIC PUBL., BASEL, CH, vol. 18, no. 2, 2000, pages
105-118, XP009002518 ISSN: 1024-2422
- ROSSI C A ET AL: "REVERSIBLE IMMOBILIZATION OF GUANINE DEAMINASE BY COVALENT CHROMATOGRAPHY"
JOURNAL OF MOLECULAR CATALYSIS, vol. 2, no. 3, 1977, pages 163-170, XP009009816 ISSN:
0304-5102
- BARAI V N ET AL: "A universal biocatalyst for the preparation of base- and sugar-modified
nucleosides via an enzymatic transglycosylation" HELVETICA CHIMICA ACTA 2002 SWITZERLAND,
vol. 85, no. 7, 2002, pages 1901-1908, XP002239460 ISSN: 0018-019X
- ESIPOV ROMAN S ET AL: "Overexpression of Escherichia coli genes encoding nucleoside
phosphorylases in the pET/Bl21 (DE3) system yields active recombinant enzymes." PROTEIN
EXPRESSION AND PURIFICATION, vol. 24, no. 1, February 2002 (2002-02), pages 56-60,
XP002239461 February, 2002 ISSN: 1046-5928
- SPOLDI E ET AL: "Recombinant bacterial cells as efficient biocatalysts for the production
of nucleosides." NUCLEOSIDES, NUCLEOTIDES & NUCLEIC ACIDS. UNITED STATES 2001 APR-JUL,
vol. 20, no. 4-7, April 2001 (2001-04), pages 977-979, XP009009766 ISSN: 1525-7770
- GAEVAIA L V ET AL: "[The use of immobilized enzymes for the synthesis of nucleosides
and nucleotides including the ones labeled with radioactive isotopes]" PRIKLADNAIA
BIOKHIMIIA I MIKROBIOLOGIIA. USSR 1987 MAY-JUN, vol. 23, no. 3, May 1987 (1987-05),
pages 309-316, XP009009807 ISSN: 0555-1099
|
|
| |
|
| Note: Within nine months from the publication of the mention of the grant of the European
patent, any person may give notice to the European Patent Office of opposition to
the European patent
granted. Notice of opposition shall be filed in a written reasoned statement. It shall
not be deemed to
have been filed until the opposition fee has been paid. (Art. 99(1) European Patent
Convention).
|
[0001] The present invention relates to the preparation of novel biocatalysts usable in
industrial processes for the production of natural nucleosides and of modified analogues
which can be used in the pharmaceutical field as intermediates or as finished products,
in the field of anti-tumour and antiviral drugs, as well as in the preparation of
intermediates for the synthesis of oligonucleotides of therapeutic interest.
[0002] Natural nucleosides, nucleoside analogue compounds and their derivatives, modified
variously either with respect to the ribofuranosyl group or with respect to the heterocyclic
base bound to the sugar, can be produced by conventional chemical synthesis methods
which, particularly for purine derivatives, present problems relating to unsatisfactory
yields and/or incomplete stereo-selectivity of the correct anomeric position and/or
to the need to use reactions for the protection/deprotection of labile chemical groups
and/or to use complex purification methods.
[0003] Alternative approaches to the preparation of nucleosides and analogues, which are
based on the use of enzymes and which may overcome the problems of preparation by
chemical synthesis, are known from scientific and patent literature.
[0004] In this field, a class of enzymes known as nucleoside phosphorylases is particularly
interesting; these catalyze both phosphorolysis reactions (consisting of the detachment
of the sugar from a nucleoside to give the corresponding sugar-1-phosphate) and the
reverse reactions (consisting of the condensation of the sugar-1-phosphate to a purine
or pyrimidine base or to a nitrated heterocyclic acceptor) to form a new nucleoside.
The combination of the two reactions, catalyzed by two phosphorylases with different
substrate specificities, enables a so-called transglycosylation reaction to be performed;
in the presence of phosphate ions, this consists of the transfer of the ribofuranosyl
or modified ribofuranosyl group from a suitable nucleoside which has the function
of a sugar donor to a suitable heterocyclic base which behaves as a sugar acceptor,
giving rise to the formation of a new nucleoside in accordance with a reaction equilibrium
which depends on the chemical/physical characteristics of the various substrates,
on their relative concentrations, and on the operative conditions used, for example,
such as pH and temperature. [
Otto J.L., Werkman C.H. Coupled nucleoside phosphorylase reactions in Escherichia
coli. Arch. Biochem. Biophys. 69, 264-276, 1957;
Doskocil J., Holy A. Specificity of purine nucleoside phosphorylase from Escherichia
coli. Collect. Czech. Chem. Commun. 42, 370-382, 1977;
Utagawa T. et al., Mechanism of purine arabinoside synthesis by bacterial transarabinosylation
reactions. 49 (8), 2425-2430, 1985].
[0005] In particular, the enzymes uridine phosphorylase or UdP (E.C. 2.4.2.3) and purine
nucleoside phosphorylase or PNP (E.C. 2.4.2.1.) have been used in combination for
the preparation of natural or modified nucleosides in transglycosylation reactions
which use various pyrimidine nucleosides such as, for example, uridine, 2'-deoxyuridine,
2'-3',-dideoxyuridine, or arabinofuranosyl uracil as sugar donors and a variety both
of natural or modified purine bases and. of nitrated heterocyclic compounds, acting
as sugar acceptors. [
Hutchinson D.W. New approaches to the synthesis of antiviral nucleosides. Trends Biotechnol.
8, 348-353, 1990;
Hanrahan J.R., Hutchinson D.W. The enzymatic synthesis of antiviral agents. J.Biotechnol.
23, 193-2120, 1992].
[0007] UdP and PNP isolated from prokaryotic microorganisms in the form of soluble enzymes
have been used as catalysts in transglycosylation reactions in homogeneous phase;
however, this approach is not very efficient and is generally limited to the laboratory
scale since it requires the use of the purified enzymes which cannot be reused for
successive reaction cycles, it does not permit operation at temperatures above 37-40°,
and it requires particularly long reaction times [
Krenitsky T.A. et al., Enzymatic synthesis of purine arabinonucleosides. EP-0002192, 1979;
Krenitsky T.A. et al. Purine nucleoside synthesis, an efficient method employing nucleoside
phosphorylase. Biochemistry 20, 3615-3621, 1981;
Krenitski T.A. et al. An enzymic synthesis of purine D-arabinonucleosides. Carbohydrate
Res. 97, 139-146, 1981;
Krenitsky T.A. et al. Imidazo [4,5-c] pyridines (3-deaza purines) and their nucleosides
as immunosuppressive and 'anti-inflammatory agents. J.Med.Chem. 29, 138-143, 1986].
[0008] The discovery that the enzymes UdP and PNP are present simultaneously in the cytoplasm
of numerous wild-type strains of microorganisms belonging to various genera, in proportions
compatible with the function of catalyzing transglycosylation reactions, has suggested
their direct use, that is, in the form of whole cell preparations, as biocatalysts
in the preparation of nucleosides and of modified analogues. The advantages of this
approach are represented by the possibility of avoiding the extraction and purification
of UdP and PNP, as well as by the stability of the cytoplasmic enzymatic activity
which enables the transglycosylation reactions to be carried out at temperatures of
up to about 60°C, thus favoring the solubilization of the substrates and increasing
the rate of reaction.
[0009] Many works have already documented the applicability of transglycosylation reactions
catalyzed by whole cells of microorganisms belonging to various species such as, for
example
Enterobacter aerogenes, Erwinia herbicola, Brevibacterium acetylicum, Escherichia
coli, both at laboratory level and on a production scale.
[0012] The use of whole bacterial cells, enabling the reactions to be carried out in heterogeneous
phase, also potentially enables the cells to be recovered for recycling in successive
reactions, although it is necessary to take into account the possibility of contamination
resulting from more or less extensive cell lysis and the fact that the recovery of
the cells complicates the production process, requiring further filtration and/or
ultrafiltration or centrifuging steps. Approaches have also been described in which
the recycling of the cells used as biocatalysts was performed with the use of cells
pre-aggregated with glutaraldehyde [
Zinchenko A.I. et al., Synthesis of 9-(β-D-arabinofuranosyl) guanine using whole cells
of Escherichia coli. Appl. Microbiol. Biotechnol. 32, 658-661, 1990;
Barai V.N. et al., A universal biocatalyst for the preparation of base- and sugar-modified
nucleosides via an enzymatic transglycosylation. Helv.Chim.Acta 85, 1901-1907, 2002], by encapsulation of the cells in hydrophilic matrices [
Votruba I. et al., Synthesis of 2-deoxy-β-D-ribonucleosides and 2-3-dideoxy-β-D-pentofuranosides
on immobilized bacterial cells. Collect.Czech.Chem.Commun. 59, 2302-2330, 1994], or by incorporation of the cells in hydrophobic polymer resins [
Yokozeki K. et al., Production of adenine arabinoside by gel-entrapped cells of Enterobacter
aerogenes in water-organic cosolvent system. Eur. J. Appl. Microbiol. Biotechnol.
14, 225-231, 1982].
[0013] Finally, the construction of genetically modified bacterial strains which can express
high levels of the recombinant forms of the enzymes UdP and PNP, both separately in
different cells and simultaneously in the same cell, [
Bestetti G. et al., Recombinant bacterial strains for the production of natural nucleosides
and modified analogues thereof. WO 00/39307, 1999] has enabled microorganisms to be obtained which can advantageously be used both
for the production of UdP and PNP [
Esipov R.S. et al., Overexpression of Escherichia coli genes encoding nucleoside phosphorylases
in the pET/B121 (DE3) system yields active recombinant enzymes. Protein Express. Purif.
24, 56-60, 2002] and for the use of the whole cells as biocatalysts in the production of natural
nucleosides and analogues by transglycosylation reactions [
Spoldi E. et al., Recombinant bacterial cells as efficient biocatalysts for the production
of nucleosides. Nucleosides Nucleotides 20 (4-7), 977-979, 2001].
[0014] However, it is generally accepted that enzymes immobilized on a solid substrate constitute
the physical form which is most advantageous for producing an industrial biocatalyst
since they enable the reactions to be carried out in heterogeneous phase, minimizing
or eliminating the problem of contamination by biological material, they can be prepared
in a physical form that is easily separable from the reaction mixture for possible
reuse, they facilitate the process for the purification of the reaction mixture, and
they simplify the production process since they are compatible with any reactor configuration
for performing both discontinuous and continuous reactions. Since the enzymatically
active forms of UdP and PNP are constituted by homo-hexameric complexes, their immobilization
on a solid substrate presents a series of problems because the immobilization process
must be compatible with the maintenance of the active oligomeric configuration [
Pugmire M.J., Ealick S.E. Structural analyses reveal two distinct families of nucleoside
phosphorylase. Biochem.J. 361, 1-25, 2002]. It has been reported that, in comparison with the methods for immobilization by
the formation of covalent bonds, methods of immobilization by non-covalent adsorption
typically disturb the structural characteristics of the enzymes much less and consequently
facilitate the maintenance of the immobilized enzyme in a configuration comparable
to the active natural configuration that is present in solution [
Bailey J.E., Ollis D.F. (a cura di). Biochemical engineering fundamentals. 2nd edition,
McGraw-Hill, New York, 1986, pag. 157].
[0016] It has now unexpectedly been found, and constitutes the principal subject of the
present invention, that the co-immobilization of both of the enzymes UdP and PNP by
the formation of covalent bonds with a solid matrix functionalized with epoxy groups
enables biocatalysts with high specific activity, excellent thermal stability, and
compatibility with high solvent concentrations to be produced. Since these novel immobilized
catalysts are easily separable from the reaction mixture and are reusable for numerous
successive reaction cycles, they are particularly suitable for industrial use and
solve the problems which have been associated with the industrial production of nucleosides
by transglycosylation reactions up to now.
[0017] A further subject of the present invention is represented by the possibility of using,
in the co-immobilization process, not only the isolated enzymes, but also the crude
soluble fractions of the enzymes UdP and PNP produced from cell cultures (where this
expression means the fraction which, after cell lysis and centrifuging, is recovered
as supernatant liquid - constituted by the lysis buffer containing the cell components,
including the enzymes which are soluble in the buffer - which is separated from the
insoluble pellet constituted by cell-wall residues and non-lysed or only partially
lysed cells); it has in fact unexpectedly been found that all of the contaminating
enzymatic activities can be completely inactivated prior to the co-immobilization
process by subjecting the cells of the microorganisms producing the enzymes to a heat
treatment at a temperature of 50-65°C and preferably at a temperature of 60°C, carried
out for a period variable from 10 minutes to 120 minutes and preferably for a period
of 30 minutes, without the heat treatment prejudicing the enzymatic activity of UdP
and PNP.
[0018] According to one embodiment of the present invention, the best results for the co-immobilization
of UdP and
[0019] PNP have been achieved by the formation of covalent bonds with a solid matrix functionalized
with oxyranic groups (epoxy groups) by means of a reaction which involves mainly the
lateral amino groups of the lysine residues that are present on the polypeptide chains
of the enzymes, in accordance with a process which does not require drastic reaction
conditions such as, for example, exposure to high temperatures or wide pH ranges,
or the use of high concentrations of chaotropic agents. It has also been found advantageous
to use, as immobilization substrates, commercially available epoxy resins for which
some technological characteristics which are important for industrial use, such as,
for example, particle size, their high density and porosity, their resistance to compression,
their resistance to microbial attack, etc., are known and guaranteed.
[0020] According to a further embodiment of the present invention, the enzymes UdP and PNP
are co-immobilized by the formation of covalent bonds on solid substrates such as,
for example, agarose gel, silica gel, polymers based on methacrylamide-bisacrylamide
or polymethacrylate polymers functionalized with epoxy groups. Amongst the various
solid substrates which are commercially available and which are usable for the co-immobilization
of UdP and PNP as described in the present invention, the following materials, amongst
others, may be mentioned: Epoxy-activated Sepharose® ; Fractogel® TSK AF-Epoxy; Eupergit®
C and Eupergit® C250L; Sepabeads® EC-EP/M and Sepabeads® EC-EP.
[0021] Although all of the materials given above can be used as substrates for the co-immobilization
of the enzymes UdP and PNP by the formation of covalent bonds, the solid substrates
constituted by methacrylic polymers functionalized with oxyranic groups (epoxy groups)
which are present at a concentration of no less than 50 µmoles/gram of moist resin
and preferably at a concentration of about 100 µmoles/gram of moist resin, have been
found particularly suitable for the preparation of a catalyst usable industrially
for the production of nucleosides. The resin Sepabeads EC-EP/M or equivalent resins
that are characterized by having a particle size variable between about 200 and 600
microns and a concentration of active epoxy groups equal to or greater than 100 µmoles/gram
of moist resin are preferably used for the co-immobilization of the enzymes UdP and
PNP in accordance with the operative methods described in the present invention.
[0022] These resins are obtainable commercially in preactivated form, that is, carrying
the epoxy groups in a state of high reactivity capable of rapidly forming covalent
bonds by reacting preferably with the ε-amino group of the lysine residues that are
present in the polypeptide chains of the enzymes to be immobilized, in accordance
with the following reaction scheme:

[0023] The. co-immobilization of the enzymes UdP and PNP on Sepabeads epoxy resins or on
equivalent resins was investigated by stirring the crude enzymatic mixture with the
immobilization substrate in the presence of a buffer with a pH of about 7-7.5 for
a period of up to 72 hours.
[0024] The final cell lysis and co-immobilization conditions were established by investigating
the following operative parameters (the optimal conditions selected for each of the
parameters investigated are given in brackets):
- a) lysis of the cell biomass and immobilization in 0.5 M, 1M, and 1.5 M phosphate
buffer (condition selected: 1M phosphate buffer)
- b) immobilization temperature about 20°C (ambient temperature) and 50°C (condition
selected: ambient temperature)
- c) contact time between the mixture of the crude cell lysates and the resin of 12
hours, 24 hours, 48 hours and 72 hours (condition selected: 48 hours)
- d) ratio between UdP enzymatic activity and PNP enzymatic activity in the mixture
of the crude cell lysates: UdP/PNP = 0.5; UdP/PNP = 1; UdP/PNP = 2; UdP/PNP = 3 (condition
selected: UdP/PNP enzymatic-activity ratio = 1)
- e) ratio between transglycosylation catalytic activity (expressed in units · ml-1 as defined in Example 3c) of the mixture of the crude cell lysates and the quantity
of resin: 90 units per 2 grams of moist resin; 90 units per 3 grams of moist resin;
90 units per 4 grams of moist resin (condition selected: approximately 90 units/3
grams of moist resin, corresponding to about 30 units/gram of moist resin)
- f) concentration of transglycosylation catalytic activity (expressed in units · ml-1 as defined in Example 3c) in the mixture of crude cell lysates of 2 units · ml-1, 6 units · ml-1, and 10 units ·ml-1 (condition selected: about 6 units · ml-1)
- g) post-immobilization treatment of the immobilized catalyst; no further treatment,
conditioning in pH 8.5 phosphate buffer, conditioning in phosphate-glycine buffer
(condition selected: no further treatment).
[0025] On the basis of the results obtained in these tests, the preparation of the immobilized
catalyst, in accordance with one of the preferred applications of the present invention,
comprises the following operative steps:
a) The enzymes UdP and PNP are produced by separate fermentation of recombinant strains
of
Escherichia coli transformed with the gene udp of
E.coli encoding for the enzyme UdP and with the gene
deoD of
E.coli encoding for the enzyme PNP, respectively. Recombinant strains usable for the production
of the enzymes UdP and PNP are similar, for example, respectively, to the strain DH5α/pGM708
(referred to as NP23/3 in the present patent) and to the strain DH5α/pGM707 (referred
to as NP24/3 in the present patent) which are described in
WO 00/39307, which is incorporated herein by reference; the characteristics of these strains
are given in Table 1. In accordance with the instructions recently issued by the international
regulatory authorities and in order to eliminate any risk of contamination by causative
agents of bovine spongiform encephalopathy, the recombinant strains NP23/3 and NP24/3
were recloned without the use of materials of animal origin; the preparation and preservation
of the cell banks and the fermentation of the recombinant strains were similarly carried
out without the use of materials of animal origin [EMEA. Note for guidance on minimising
the risk of transmitting animal spongiform encephalopathy agents via human and veterinary
medicinal products. 2001].
Table 1. Characteristics of the recombinant strains of Escherichia coli that are producers
of UdP and PNP
| Strain |
Protein cloned |
Selection marker |
| NP23/3 |
Uridine phosphorylase (UdP) |
Tetracycline |
| NP24/3 |
Purine nucleoside phosphorylase (PNP) |
Tetracycline |
b) After thermal treatment at 60° for 30 minutes in order to inactivate the contaminating
enzymatic activities, the biomasses obtained in the two fermentations are subjected
to mechanical lysis (or alternatively to lysis by sonication and to chemical and/or
enzymatic lysis) and centrifuged to separate the crude soluble fractions; the mixture
of the two soluble fractions is then used directly for the immobilization without
further purification steps.
c) The crude cell lysates containing UdP and PNP are mixed so as to have UdP : PNP
enzymatic-activity ratios variable from 1 : 0.5 to 1 : 3 (and preferably a ratio of
about 1: 1) and are put in contact with the immobilization substrate.
d) The immobilization substrate is constituted by an acrylic resin functionalized
with epoxy groups, and preferably by the resin Sepabeads EC-EP/M, and is used in a
proportion of about 2-3 kg of moist resin to immobilize 10 litres of mixture of crude
cell lysates having a transglycosylation catalytic activity of about 6 units · ml
-1.
[0026] As an alternative to the method given above, the crude cell lysates containing the
enzymes UdP and PNP may be immobilized separately by using a method similar to the
method described for the co-immobilization of the two enzymes and then mixed for use
as catalysts of the transglycosylation reactions.
[0027] The use of recombinant strains for the production of the enzymes UdP and PNP enables
large cell biomass quantities to be obtained and enables cell lysates to be extracted
with a high enzyme titre, as shown in Tables 2 and 3 below.
Table 2. Production of UdP by fermentation of the recombinant strain NP23/
3
| Fermentation |
Cell Biomass*
Grams/litre |
UdP Activity**
Units/litre |
| 1 |
162 |
476300 |
| 2 |
160 |
376300 |
| 3 |
185 |
511400 |
| 4 |
160 |
480000 |
| * The cell biomass is given as moist weight |
| ** The enzymatic activity is measured on the cell lysate and relates to the phosphorolysis
of uridine reaction |
Table 3.
Production of PNP by fermentation of the recombinant strain NP24/
3
| Fermentation |
Cell biomass* Grams/litre |
UdP Activity** Units/litre |
| 1 |
185 |
111000 |
| 2 |
166 |
87150 |
| 3 |
165 |
111400 |
| 4 |
168 |
100800 |
| * The cell biomass is given as moist weight |
| ** The enzymatic activity is measured on the cell lysate and relates to the phosphorolysis
of inosine reaction |
[0028] In the co-immobilization method, the crude cell lysates containing UdP and PNP can
be mixed in different proportions so as to obtain a catalyst which is optimized for
each transglycosylation reaction of interest. For example, it has been found that,
by starting with lysate mixtures with UdP: PNP enzymatic-activity ratios variable
from 2 : 1 to 1 : 2, immobilized catalysts are obtained that are optimal for use in
most of the glycosylation reactions which use ribofuranosyl uracil, 2'-deoxyribofuranosyl
uracil, 2'-3'-deoxyribofuranosyl uracil and arabinofuranosyl uracil as sugar donors.
[0029] In the operative conditions described, a catalyst which has the analytical characteristics
given in Table 4 is obtained with a yield of the co-immobilizations process, calculated
as the transglycosylation catalytic activity, of about 50-70%.
Table 4.
Analytical characteristics of the catalyst obtained by co-immobilization of the enzymes
UdP and PNP by the formation of covalent bonds on resin functionalized with epoxy
groups
| Parameters |
Characteristics* |
| Appearance |
White-brown granules |
| Particle size |
200-600 micrometres |
| Water |
40-60% |
| pH |
6-8 |
| Enzymatic Activity** |
10-20 units/gram |
| * Relating to the filtered moist resin |
| ** Transglycosylation catalytic activity determined as described in Example 3c. |
[0030] The immobilized enzyme preparation is preserved at 4°C as moist resin in 100 mM potassium
phosphate buffer - 20% isopropanol - pH 7 - 500 ppm ethyl p-hydroxy benzoate. In these
conditions, complete maintenance of the transglycosylation catalytic activity has
been confirmed in a stability study carried out for up to 6 months.
[0031] The method of the present invention for the covalent co-immobilization of the enzymes
UdP and PNP permits the preparation of a novel form of immobilized catalyst which
is stable up to temperatures of 60 - 70°C, is compatible with the presence of a high
concentration of water-miscible solvents, such as, for example, alcohols, ethylene
and polyethylene glycols, dimethyl sulphoxide, and tetrahydrofuran, and which maintains
a good enzymatic activity within the pH range of from 6 to 9.
[0032] According to a further application of the present invention, the enzymes UdP and
PNP, immobilized on a solid substrate functionalized with epoxy groups by the formation
of covalent bonds, are advantageously usable for the industrial preparation of natural
nucleosides and analogues modified by transglycosylation reactions starting with a
sugar-donor nucleoside and a sugar-acceptor base. The immobilized catalyst of the
present invention has characteristics of enzymatic efficiency and stability and mechanical
properties such as to enable transglycosylation reactions to be carried out at about
50-60°C, to enable the reaction mixture to be separated easily form the catalyst upon
completion of the reaction (for example, by direct filtration on a porous partition
welded to the reaction vessel) and enables the same catalyst to be reused for successive
reaction cycles as described in greater detail in the examples given below.
[0033] Thus, for example, in a cycle of 12 successive reactions carried out at 60°C for
2.5 hours for the preparation of β-D-arabinofuranosyl 2,6 diaminopurine (Ara-DAMP)
in which, in each reaction, the resin recovered in the previous reaction was reused
as catalyst, it was found that the resin recovered after the last cycle (for a total
period of operative use at 60°c of 30 hours) had retained more than 85% of its initial
catalytic activity. The stability of the catalyst was further investigated at 60°C,
50°C and 40°C for continuous operative periods of up to 240 hours (10 days); the results
obtained indicated a mean loss of catalytic efficiency of 8% per 24 hours of operative
use at a temperature of 60°C, and of 5% per 24 hours of operative use at a temperature
of 50°C whereas, at a temperature of 40°C, the mean loss of catalytic efficiency per
24 hours of operative use was less than 0.5%.
[0034] According to a further application of the present invention, the immobilized catalyst
is also usable in reactions which use substrates that are poorly soluble in aqueous
buffers, as is the case with the preparation of fludarabine desphosphate which is
described in one of the examples given below in which the presence of 40% of dimethyl
sulphoxide in the reaction mixture, which was heated to a temperature of 60°C, did
not modify the activity of the immobilized catalyst.
[0035] According to a further application of the present invention, the immobilized catalyst
can be used in transglycosylation reactions carried out in a continuous reactor. The
reactor may advantageously be constituted by a thermostatically controlled column;
the reaction mixture, containing the sugar-donor nucleoside, the acceptor base, and
the phosphate buffer as described in one of the examples given below, which relates
to the preparation of 2'-deoxyadenosine, is passed through the column by gravity or,
preferably, by means of a calibrated-flow pump. By adjusting the flow of the reaction
mixture through the catalyst bed in relation to the rate of the transglycosylation
reaction (in the conditions used for the production of 2'-deoxyadenosine, the optimal
flow was 1/5 of the column volume/minute) the enzymatic reaction reaches equilibrium
in the time taken to pass through the catalyst and the eluate of the column can be
used directly for the purification of the new nucleoside formed in the reaction.
[0036] The following examples are intended to illustrate the present invention without constituting
a limitation of its field of application.
Example No. 1.
Fermentation of recombinant strains which are producers of UdP and PNP
[0037] The recombinant strains NP23/3 and NP24/3 which express the enzymes UdP and PNP,
respectively, were fermented separately in fed-batch conditions with the use of fermenters
with a useful fermentation volume of 10 litres, containing 8 litres of culture medium
at pH 6.8-7.0 having the following composition (per litre): 13.3 g KH
2PO
4; 4.0 g (NH
4)
2HPO
4; 1.7 g citric acid, 1.25 g soitone; 2.5 g glycerol; 0.125 g yeast extract; 1.5 g
MgSO
4.7H
2O; 0.08 g CaCl
2; 0.08 g FeSO
4.7H
2O; 0.02 g MnSO
4.H
2O; 0.03 g ZnSO
4.7H
2O; 0.003 g H
3BO
3; 0.006 g CuSO
4.5H
2O; 0.008 g CoCl
2.6H
2O; 0.004 g NaMoO
4.2H
2O; 0.010 g thiamine.HCl, 0.0125 g tetracycline. The fermenter was inoculated at an
initial OD
600 value of 0.4 with about 300 ml of bacterial suspension previously grown for about
20 hours at 30°C. The fermentation was carried out with the use of the following operative
parameters: temperature 30°C; air flow of 1 volume/volume of bouillon culture/minute;
initial stirring of 150 revolutions/minute increased automatically to keep the pO
2 value at 20% of the saturation concentration for 10 hours (batch phase) and then
at 10% of the saturation concentration; pH kept at 7.0 ±0.1 by automatic addition
of a solution of 12.5% NH
4OH or of a 25% solution of H
3PO
4. During the fed-batch phase (from 10 hours after the start of fermentation and up
to about 50 hours), 2 litres of a solution having the following composition (per litre)
was added automatically to the fermenter: 400 g glycerol; 200 g soitone; 20 g yeast
extract; 3 g MgSO
4.7H
2O; 0.0125 g tetracycline. Upon completion of the fermentation (which was completed
in about 51-52 hours) the cell biomass was collected by centrifuging, washed in 30
mM phosphate buffer - pH 7, recentrifuged, and kept as moist cell biomass at a temperature
of - 20°C.
Example No. 2
Cell lysis
[0038]
- a) 400 grams of moist cell paste, separated by centrifuging or by microfiltration
from a bouillon culture of the recombinant strain NP23/3 which expresses the enzyme
UdP, was resuspended to give a volume of 1.5 litres with 1M phosphate buffer - pH
7.5 and heated with stirring to 56-60°C for 30 minutes. After cooling to about 4°C,
the suspension was lysed by means of three consecutive steps at a pressure of about
600 bar in a Manton-Gaulin mechanical homogenizer with the temperature kept at about
10°C. The suspension was clarified by centrifuging at 12,000 x g, giving about 2 litres
of solution containing the total soluble proteins.
- b) 1600 grams of moist cell paste, separated by centrifuging from a bouillon.culture
of the recombinant strain NP24/3 which expresses the enzyme PNP, was resuspended to
give a volume of 8 litres with 1M phosphate buffer - pH 7.5 and heated with stirring
to 56-60°C for 30 minutes. After cooling to about 4°C, the suspension was lysed by
means of three consecutive steps at a pressure of about 600 bar in a Manton-Gaulin
mechanical homogenizer with the temperature kept at about 10°C. The suspension was
clarified by centrifuging at 12,000 x g, giving about 8 litres of solution containing
the total soluble proteins.
Example No. 3.
Determination of enzymatic activities
[0039]
- a) Determination of the enzymatic activity of UdP.
A measured volume (from 100 to 200 microlitres) of centrifuged lysate, diluted 1:100
v/v, extracted from the cell paste which expressed UdP, was added to 800 microlitres
of a 75 mM solution of uridine in 100 mM potassium phosphate buffer - pH 7, preincubated
at 30°C. After 5 minutes, the uridine → uracil phosphorolysis reaction was stopped
by the addition of 1 ml 1N HCl. An aliquot of the reaction mixture was analyzed by
high pressure liquid chromatography (HPLC) with the use of a 250 x 4.6 mm, 5 µm spheres,
C-18 Capcell-Pack column (Shisheido) eluted with a 30 mM solution of monobasic ammonium
phosphate - pH 4.5 - 9% methanol. The enzymatic activity of the cell lysate was expressed
as units · ml-1 (µmoles of uracil · min-1 · ml-1) and was calculated relative to a standard uracil solution eluted in the same conditions.
- b) Determination of PNP enzymatic activity.
A measured volume (variable from 100 to 200 microlitres) of centrifuged lysate diluted
1:100 v/v, extracted from the cell paste of the strain which expresses PNP, was added
to 800 microlitres of a 62.5 mM solution of inosine in 100 mM potassium phosphate
buffer - pH 7, preincubated at 30°C. After 10 minutes, the inosine → hypoxanthine
phosphorolysis reaction was stopped by the addition of 1 ml of 1N HCl. An aliquot
of the reaction mixture was analyzed by high pressure liquid chromatography (HPLC)
with the use of a 250 x 4.6mm, 5 µm spheres, C-18 Capcell-Pack column (Shisheido)
eluted with a 30 mM solution of monobasic ammonium phosphate - pH 4.5 - 9% methanol.
The enzymatic activity of the cell lysate was expressed as units · ml-1 (µmoles of hypoxanthine · min-1 · ml-1) and was calculated relative to a standard hypoxanthine solution eluted in the same
conditions.
- c) Determination of transglycosylation catalytic activity.
The transglycosylation catalytic activity of the mixture of cell lysates containing
UdP and PNP or of the enzymes UdP and PNP co-immobilized on a solid substrate was
determined in a transglycosylation reaction carried out on analytical scale in standardized
conditions.
250 µl of the mixture of cell lysates or 100 mg (moist weight) of immobilized UdP-PNP
catalyst was added to 10 ml of a solution having the following composition: 40 mM
β-D-arabinofuranosyl uracil (Ara-U), 40 mM adenine, 30 mM potassium phosphate buffer
- pH 7, thermostatically controlled at 60°C. After 1.5 hours at 60°C, the reaction
was stopped by diluting the mixture 1:50 and cooling in ice. The percentage of bioconversion
of adenine to β-D-arabinofuranosyl adenine (Ara-A) was determined by analyzing an
aliquot of the reaction mixture by high pressure liquid chromatography (HPLC) with
the use of a 250 x 4.6 mm, 5 µm spheres, C-18 Capcell-Pack column (Shisheido), eluted
with a 30 mM solution of monobasic ammonium phosphate, pH 4.5 - 9% methanol. The transglycosylation
catalytic activity was expressed as units · ml-1 (µmoles of Ara-A formed in 1.5 hours · ml-1 of mixture of cell lysates) or in units · g-1 of moist resin (µmoles of Ara-A formed in 1.5 hours · g-1 of moist resin) and was calculated relative to a standard Ara-A solution eluted by
HPLC in the same conditions.
Example No. 4.
Preparation of the catalyst by co-immobilization of UdP and PNP
[0040] The co-immobilization of the enzymes UdP and PNP was carried out starting with a
mixture of the lysates prepared so as to have a UdP and PNP activity ratio variable
within the range of from 1 : 0.5 to 1 : 4. In this example, immobilization starting
with a mixture of lysates in which the UdP : PNP activity ratio was 1 : 1 is described.
[0041] 2.6 kg (moist weight, containing about 40-50% of H
2O) of Sepabeads EC-EP/M epoxy resin (Resindion Srl, Milan) and 500 parts per million
of p-hydroxymethyl benzoate was added to a mixture of 2 litres of crude cell lysate
containing a UdP activity of about 500 units/ml and 8 litres of crude cell lysate
containing a PNP activity of about 125 units/ml. The mixture was kept at ambient temperature
with gentle stirring for 48 hours; the mixture was left to clear, the supernatant
liquid was removed, the resin was filtered under vacuum in a Buchner filter and was
washed, on the filter, with about 20 litres of deionized.water.
[0042] The immobilized catalyst was characterized by determining the transglycosylation
activity and was kept at 4°C in 100 mM phosphate buffer - 20% propanol - 500 ppm ethyl
p-hydroxybenzoate.
Example No. 5
Examples of preparation of nucleosides by the transglycosylation reaction catalyzed
by the enzymes UdP and PNP co-immobilized by covalent bonds on a solid substrate
[0043]
- a) Preparation of Ara-A
10 grams (moist weight) of immobilized catalyst with transglycosylation activity of
about 12 units/gram, previously filtered from the preservation solution and washed
on the filter with deionized water, was added to 150 ml of a solution kept thermostatically
at 60°C and having the following composition:
25 mM Ara-U
25 mM adenine
30 mM potassium phosphate buffer, pH 7.
After 1 hour at 60°C, the catalyst was discharged (and was made to react in a new
bioconversion reaction) and the filtrate was cooled in order to recover the precipitate,
constituted by crude Ara-A, which was purified by crystallization from water.
The bioconversion yield of the reaction was ≥ 70%. The purity of Ara-A after crystallization,
determined by HPLC analysis, was greater than 98%.
- b) Preparation of β-D-arabinofuranosyl adenine (Ara-DAMP)
65 grams (moist weight of immobilized catalyst with transglycosylation activity of
about 13 units/gram, previously filtered from the preservation solution and washed
on the filter with deionized water, was added to 2 litres of a solution kept thermostatically
at 60°C and having the following composition:
30 mM Ara-U
30 mM 2,6-diaminopurine (DAMP)
30 mM potassium phosphate buffer, pH 7.
After 2.5 hours at 60°C, the catalyst was discharged (and was made to react in a new
bioconversion reaction) and the filtrate was cooled in order to recover the precipitate,
constituted by crude Ara-DAMP, which was purified by crystallization from water.
The bioconversion yield of the reaction was ≥ 70%. The purity of Ara-DAMP after crystallization,
determined by HPLC analysis, was greater than 98%.
- c) Preparation of β-D-arabinofuranosyl-2-fluoroadenine des-phosphate (fludarabine
des-phosphate) 30 grams (moist weight) of immobilized catalyst with transglycosylation
activity of about 13 units/gram, previously filtered from the preservation solution
and washed on the filter with deionized water, was added to 800 ml of a solution containing
40% of dimethyl sulphoxide (DMSO) kept thermostatically at 60°C and having the following
composition:
75 mM Ara-U
50 mM 2-fluoro-adenine
30 mM potassium phosphate buffer, pH 7.
After 4 hours at 60°C, the catalyst was discharged (and was made to react in a new
bioconversion reaction) and the filtrate was cooled in order to recover the precipitate,
constituted by crude fludarabine desphosphate, which was purified by crystallization
from a DMSO/water mixture.
The bioconversion yield of the reaction was ≥ 70%. The purity of fludarabine des-phosphate
after crystallization, determined by HPLC analysis, was greater than 98%:
- d) Preparation of 2'-deoxyadenosine
1 gram (moist weight). of immobilized catalyst with transglycosylation activity of
about 13 units/gram, previously filtered from the preservation solution and washed
on the filter with deionized water, was added to 200 ml of a solution kept thermostatically
at 60°C and having the following composition:
75 mM 2'-deoxyuridine
50 mM adenine
30 mM phosphate buffer pH 7.
[0044] After 2 hours at 60°C the catalyst was discharged (and was made to react in a new
bioconversion reaction) and the filtrate was cooled in order to recover the precipitate,
constituted by 2'-deoxyadenosine, which was purified by precipitation from H
2O. The bioconversion yield of the reaction was ≥ 70%. The purity of the 2'-deoxyadenosine
after crystallization, determined by HPLC analysis, was greater than 98%.
- a) Preparation of 2'-deoxyguanosine
5 grams (moist weight) of immobilized catalyst with transglycosylation activity of
about 13 units/gram, previously filtered from the preservation solution and washed
on the filter with deionized water, was added to 90 ml of a solution kept thermostatically
at 60°C and having the following composition:
60 mM 2'-deoxyuridine
30 mM phosphate buffer pH 7.
5 ml of an 0.8M solution of guanine in 30% NaOH was added very slowly (2.5 ml/hour),
whilst the reaction mixture was kept at pH 7 by the continuous addition of 20% HCl.
After 2.5 hours at 60°C, the catalyst was discharged (and was made to react in a new
bioconversion reaction) and the filtrate was cooled to 50°C in order to eliminate
the unreacted guanine by filtration. The filtrate was then cooled to 4°C in order
to precipitate the 2' -deoxyguanosine which was purified by crystallization from H2O. The bioconversion yield of the reaction was ≥ 70%. The purity of the 2'-deoxyguanosine
after crystallization, determined by HPLC analysis was greater than 98%.
- a) Preparation of (N'-β-D-ribofuranosyl)- 5-hydroxyimidazolo-4-carboxamide (mizoribine).
5 grams (moist weight) of immobilized catalyst with transglycosylation activity of
about 12 units/gram, previously filtered from the preservation solution and washed,
on the filter, with deionized water, was added to 100 ml of a solution kept thermostatically
at 60°C and having the following composition:
225 mM uridine
150 mM hydroxycarbamoyl-imidazole
30 mM potassium phosphate buffer, pH 7.
After 6 hours at 60°C the catalyst was discharged (and was made to react in a new
bioconversion reaction), the filtrate was cooled, and the mizoribine was purified
therefrom by chromatography in an ion-exchange column.
The bioconversion yield of the reaction was ≥ 80%. The purity of mizoribine, determined
by HPLC analysis, was greater than 98%.
[0045] a) Preparation of 2'-deoxyadenosine in a continuous reactor.
[0046] A preparation of immobilized catalyst with transglycosylation activity of about 12
units/gram was packed to a height of 4 cm in a column kept thermostatically at a temperature
of 40°C and having a diameter of 2 cm, (column volume = 12.5 ml). 3 litres of a solution
preheated to 40°C and containing 10 mM adenine, 15 mM 2'-deoxyuridine and 30 mM phosphate
buffer, pH 7, was pumped through the column of catalyst by means of a pump with a
calibrated flow of 2.5 ml/minute (flow rate = 1/5 of the column volume/minute). Aliquots
of the eluate were collected after 30 and 60 minutes and then at 2-hourly intervals
up to 20 hours and were analyzed by HPLC to determine the bioconversion yield which
was within the range between 83% and 86% for all of the samples.
1. Biocatalyst usable for transglycosylation reactions, containing a solid matrix functionalized
with epoxy groups and the enzymes uridine phosphorylase and purine nucleoside phosphorylase,
characterized in that the enzymes uridine phosphorylase and purine nucleoside phosphorylase are co-immobilized
on the solid matrix by the formation of covalent bonds.
2. Biocatalyst according to Claim 1, characterized in that the covalent bonds are produced by reaction between the epoxy groups of the solid
matrix and the amino groups of the enzymes.
3. Biocatalyst according to Claim 2, characterized in that the amino groups are amino groups of the lysine residues present on the polypeptide
chains of the enzymes.
4. Biocatalyst according to Claims 1-3, characterized in that the solid matrix has a concentration of epoxy groups no less than 50 µmoles/gram
of moist resin, preferably a concentration of about 100 µmoles/gram of moist resin.
5. Biocatalyst according to Claims 1-3, characterized in that the solid matrix is an epoxy resin.
6. Biocatalyst according to Claim 5, characterized in that the epoxy resin is selected from Epoxy-activated Sepharose ® Fractogel® TSK AF-Epoxy, Eupergit® C, Eupergit® C250L, Sepabeads® EC-EP/M and Sepabeads® EC-EP.
7. Biocatalyst according to Claim 5, characterized in that the epoxy resin has a particle size of between 200 and 600 microns.
8. Biocatalyst according to Claims 1-3, characterized in that the solid matrix is an agarose gel functionalized with epoxy groups, a silica gel
functionalized with epoxy groups, a polymer based on methacrylamide-bisacrylamide
functionalized with epoxy groups, or a polymethacrylate polymer functionalized with
epoxy groups.
9. Biocatalyst according to Claims 1-8, characterized in that the enzymes UdP and PNP are of prokaryotic origin.
10. Biocatalyst according to Claims 1-8, characterized in that the enzymes UdP and PNP are produced by a recombinant method.
11. Biocatalyst according to Claim 10, characterized in that the enzymes UdP and PNP are contained in the crude soluble portion extracted from
the recombinant cells or in partially purified or purified preparations derived from
the crude soluble portion extracted from the recombinant cells.
12. Use of the biocatalyst according to Claims 1 to 11 for the production of nucleosides
by an enzymatic transglycosylation reaction between a sugar-donor nucleoside and a
heterocyclic sugar-acceptor base.
13. Use according to Claim 12, characterized in that the sugar of the donor nucleoside is β-D-ribose, 2'deoxy-β-D-ribose, 2'-3'-dideoxy-β-D-ribose,
β-D-arabinose, α-L-xylose, or amino-derivatives or halo-derivatives thereof.
14. Use according to Claim 12, characterized in that the base of the donor nucleoside is uracil.
15. Use according to Claims 12 to 14, characterized in that the transglycosylation reaction is carried out in aqueous phase.
16. Use according to Claims 12 to 14, characterized in that the transglycosylation reaction is carried out in the presence of phosphate buffer.
17. Use according to Claims 12 to 14, characterized in that the transglycosylation reaction is carried out at a pH of between 6 and 8, preferably
between 6.5 and 7.5.
18. Use according to Claims 12 to 14, characterized in that the transglycosylation reaction is carried out at temperatures of up to 75°C and
preferably at temperatures of between 55 and 60°C.
19. Use according to Claims 12 to 18, characterized in that, upon completion of the reaction, the immobilized catalyst is separated from the
reaction mixture by filtration, decantation, or centrifugation and is reused in successive
transglycosylation reactions.
20. Use according to Claims 12 to 18, characterized in that the transglycosylation reaction is carried out in a continuous system in which the
reaction is completed by passage through the biocatalyst which is kept in a column
or in a thermostatically controlled continuous reactor.
21. Method for the preparation of a biocatalyst according to Claims 1 to 11, characterized in that the enzymes uridine phosphorylase and purine nucleoside phosphorylase are put in
contact with the solid matrix, functionalized with epoxy groups, with stirring, at
a pH of between 6 and 9, and at a temperature of between 10 and 50°C.
22. Method according to Claim 21, characterized in that the enzymes uridine phosphorylase and purine nucleoside phosphorylase are put separately
in contact with two distinct fractions of the solid matrix which are then mixed together
to give the biocatalyst.
23. Method according to Claims 21-22, characterized in that the enzymes uridine phosphorylase and purine nucleoside phosphorylase are used in
uridine phosphorylase : purine nucleoside phosphorylase enzymatic-activity ratios
of between 1 : 0.5 and 1 : 3, preferably in a ratio of about 1 : 1.
24. Method according to Claims 21-23, characterized in that (a) the biomass obtained by the fermentation of bacterial strains expressing the
enzymes uridine phosphorylase and purine nucleoside phosphorylase are subjected to
lysis and centrifuged to separate the crude soluble fractions, (b) the mixture of
the crude soluble fractions thus obtained is put in contact with the solid matrix
functionalized with epoxy groups without further purification steps.
25. Method according to Claim 24, characterized in that a single bacterial strain which simultaneously expresses the enzymes uridine phosphorylase
and purine nucleoside phosphorylase is used, or two distinct bacterial strains one
expressing the enzyme uridine phosphorylase and the other the enzyme purine nucleoside
phosphorylase are used.
26. Method according to Claims 24-25, characterized in that the bacterial strains are recombinant.
27. Method according to Claims 24-26, characterized in that, prior to step (a), the biomass is subjected to a heat treatment at a temperature
of 50-70°C, preferably at, 60°C.
28. Method according to Claim 27, characterized in that the heat treatment is performed for 20-40 minutes, preferably for 30 minutes.
29. A biocatalyst that can be produced by the method according to Claims 21-28.
1. Biokatalysator, der für Transglycosylierungsreaktionen geeignet ist, enthaltend eine
feste Matrix funktionalisiert mit Epoxygruppen und die Enzyme Uridinphosphorylase
und Purinnucleosidphosphorylase, dadurch gekennzeichnet, dass die Enzyme Uridinphosphorylase und Purinnucleosidphosphorylase auf der festen Matrix
durch die Bildung von kovalenten Bindungen co-immobilisiert sind.
2. Biokatalysator nach Anspruch 1, dadurch gekennzeichnet, dass die kovalenten Bindungen durch Reaktion zwischen den Epoxygruppen der festen Matrix
und den Aminogruppen der Enzyme gebildet werden.
3. Biokatalysator nach Anspruch 2, dadurch gekennzeichnet, dass die Aminogruppen Aminogruppen der Lysinreste sind, die in den Polypeptidketten der
Enzyme vorhanden sind.
4. Biokatalysator nach den Ansprüchen 1 bis 3, dadurch gekennzeichnet, dass die feste Matrix eine Konzentration von Epoxygruppen von nicht weniger als 50 µmol/g
feuchtem Harz, bevorzugt eine Konzentration von etwa 100 µmol/g feuchtem Harz, aufweist.
5. Biokatalysator nach den Ansprüchen 1 bis 3, dadurch gekennzeichnet, dass die feste Matrix ein Epoxyharz ist.
6. Biokatalysator nach Anspruch 5, dadurch gekennzeichnet, dass das Epoxyharz ausgewählt ist aus Epoxy-aktivierter Sepharose®, Fractogel® TSK AF-Epoxy, Eupergit® C, Eupergit® C250L, Sepabeads® EC-EP/M und Sepabeads® EC-EP.
7. Biokatalysator nach Anspruch 5, dadurch gekennzeichnet, dass das Epoxyharz eine Teilchengröße zwischen 200 und 600 Mikron aufweist.
8. Biokatalysator nach den Ansprüchen 1 bis 3, dadurch gekennzeichnet, dass die feste Matrix ein mit Epoxygruppen funktiortalisiertes Agarosegel, ein mit Epoxygruppen
funktionalisiertes Silicagel, ein mit Epoxygruppen funktionalisiertes Polymer auf
Basis von Methacrylamid-Bisacrylamid oder ein mit Epoxygruppen funktionalisiertes
Polymethacrylat-Polymer ist.
9. Biokatalysator nach den Ansprüchen 1 bis 8, dadurch gekennzeichnet, dass die Enzyme UdP und PNP prokaryotischen Ursprungs sind.
10. Biokatalysator nach den Ansprüchen 1 bis 8, dadurch gekennzeichnet, dass die Enzyme UdP und PNP durch ein rekombinantes Verfahren gebildet werden.
11. Biokatalysator nach Anspruch 10, dadurch gekennzeichnet, dass die Enzyme UdP und PNP in dem aus den rekombinanten Zellen extrahierten rohen löslichen
Anteil oder in teilweise gereinigten oder gereinigten Zubereitungen, die von dem aus
den rekombinanten Zellen extrahierten rohen löslichen Anteil abgeleitet sind, enthalten
sind.
12. Verwendung des Biokatalysators nach den Ansprüchen 1 bis 11 für die Herstellung von
Nucleosiden durch eine enzymatische Transglycosylierungsreaktion zwischen einem Zucker-Donornucleosid
und einer heterocyclischen Zucker-Akzeptorbase.
13. Verwendung nach Anspruch 12, dadurch gekennzeichnet, dass der Zucker des Donornucleosids β-D-Ribose, 2'-Deoxy-β-D-ribose, 2'-3'-Dideoxy-β-D-ribose,
β-D-Arabinose, α-L-Xylose oder Aminoderivate oder Halogenderivate davon ist.
14. Verwendung nach Anspruch 12, dadurch gekennzeichnet, dass die Base des Donornucleosids Uracil ist.
15. Verwendung nach den Ansprüchen 12 bis 14, dadurch gekennzeichnet, dass die Transglycosylierungsreaktion in wässriger Phase durchgeführt wird.
16. Verwendung nach den Ansprüchen 12 bis 14, dadurch gekennzeichnet, dass die Transglycosylierungsreaktion in Anwesenheit von Phosphatpuffer durchgeführt wird.
17. Verwendung nach den Ansprüchen 12 bis 14, dadurch gekennzeichnet, dass die Transglycosylierungsreaktion bei einem pH zwischen 6 und 8, bevorzugt zwischen
6,5 und 7,5, durchgeführt wird.
18. Verwendung nach den Ansprüchen 12 bis 14, dadurch gekennzeichnet, dass die Transglycosylierungsreaktion bei Temperaturen von bis zu 75°C und bevorzugt bei
Temperaturen zwischen 55 und 60°C durchgeführt wird.
19. Verwendung nach den Ansprüchen 12 bis 18, dadurch gekennzeichnet, dass nach Vervollständigung der Reaktion der immobilisierte Katalysator aus der Reaktionsmischung
durch Filtrieren, Dekantieren oder Zentrifugieren abgetrennt wird und in nachfolgenden
Transglycosylierungsreaktionen wiederverwendet wird.
20. Verwendung nach den Ansprüchen 12 bis 18, dadurch gekennzeichnet, dass die Transglycosylierungsreaktion in einem kontinuierlichen System durchgeführt wird,
in dem die Reaktion durch Hindurchleiten durch den Biokatalysator vervollständigt
wird, der in einer Säule oder in einem thermostatisch gesteuerten kontinuierlichen
Reaktor gehalten wird.
21. Verfahren zur Herstellung eines Biokatalysators nach den Ansprüchen 1 bis 11, dadurch gekennzeichnet, dass die Enzyme Uridinphosphorylase und Purinnucleosidphosphorylase unter Rühren bei einem
pH zwischen 6 und 9 und bei einer Temperatur zwischen 10 und 50°C mit der mit Epoxygruppen
funktionalisierten festen Matrix in Kontakt gebracht werden.
22. Verfahren nach Anspruch 21, dadurch gekennzeichnet dass die Enzyme Uridinphosphorylase und Purinnucleosidphosphorylase gesondert mit zwei
verschiedenen Fraktionen der festen Matrix in Kontakt gebracht werden, die dann zusammengemischt
werden, um den Biokatalysator zu ergeben.
23. Verfahren nach den Ansprüchen 21-22, dadurch gekennzeichnet, dass die Enzyme Uridinphosphorylase und Purinnucleosidphosphorylase in enzymatischen Aktivitätsverhältnissen
Uridinphosphorylase : Purinnucleosidphosphorylase zwischen 1 : 0,5 und 1 : 3, bevorzugt
in einem Verhältnis von etwa 1 : 1, verwendet werden.
24. Verfahren nach den Ansprüchen 21 bis 23, dadurch gekennzeichnet, dass (a) die Biomasse, die durch Fermentation von Bakterienstämmen, die die Enzyme Uridinphosphorylase
und Purinnucleosidphosphorylase exprimieren, erhalten wird, einer Lysis unterworfen
wird und zentrifugiert wird, um die löslichen Rohfraktionen zu trennen, (b) die Mischung
der so erhaltenen löslichen Rohfraktionen ohne weitere Reinigungsschritte mit der
mit Epoxygruppen funktionalisierten festen Matrix in Kontakt gebracht wird.
25. Verfahren nach Anspruch 24, dadurch gekennzeichnet, dass ein Bakterienstamm, der gleichzeitig die Enzyme Uridinphosphorylase und Purinnucleosidphosphorylase
exprimiert, verwendet wird oder zwei verschiedene Bakterienstämme verwendet werden,
wobei einer das Enzym Uridinphosphorylase exprimiert und der andere das Enzym Purinnucleosidphosphorylase.
26. Verfahren nach den Ansprüchen 24-25, dadurch gekennzeichnet, dass die Bakterienstämme rekombinant sind.
27. Verfahren nach den Ansprüchen 24 bis 26, dadurch gekennzeichnet, dass vor Schritt (a) die Biomasse einer Wärmebehandlung bei einer Temperatur von 50 bis 70°C,
bevorzugt bei 60°C, unterworfen wird.
28. Verfahren nach Anspruch 27, dadurch gekennzeichnet, dass die Wärmebehandlung 20 bis 40 Minuten, bevorzugt 30 Minuten, durchgeführt wird.
29. Biokatalysator, der durch das Verfahren nach den Ansprüchen 21 bis 28 hergestellt
werden kann.
1. Biocatalyseur utilisable pour des réactions de transglycosylation, contenant une matrice
solide fonctionnalisée avec des groupes époxy et les enzymes uridine phosphorylase
et purine nucléoside phosphorylase, caractérisé en ce que les enzymes uridine phosphorylase et purine nucléoside phosphorylase sont co-immobilisées
sur la matrice solide par la formation de liaisons covalentes.
2. Biocatalyseur selon la revendication 1, caractérisé en ce que les liaisons covalentes sont produites par réaction entre les groupes époxy de la
matrice solide et les groupes amino des enzymes.
3. Biocatalyseur selon la revendication 2, caractérisé en ce que les groupes amino sont les groupes amino des résidus lysine présents sur les chaînes
polypeptidiques des enzymes.
4. Biocatalyseur selon les revendications 1 à 3, caractérisé en ce que la matrice solide a une concentration de groupes époxy non inférieure à 50 µmoles/gramme
de résine humide, de préférence une concentration d'environ 100 µmoles/gramme de résine
humide.
5. Biocatalyseur selon les revendications 1 à 3, caractérisé en ce que la matrice solide est une résine époxy.
6. Biocatalyseur selon la revendication 5, caractérisé en ce que la résine époxy est choisie parmi la Sepharose ® époxy-activée, le Fractogel® TSK
AF-Epoxy, l'Eupergit® C, l'Eupergit® C250L, le Sepabeads® EC-EP/M et le Sepabeads®
EC-EP.
7. Biocatalyseur selon la revendication 5, caractérisé en ce que la résine époxy a une granulométrie comprise entre 200 et 600 micromètres.
8. Biocatalyseur selon les revendications 1 à 3, caractérisé en ce que la matrice solide est un gel d'agarose fonctionnalisé avec des groupes époxy, un
gel de silice fonctionnalisé avec des groupes époxy, un polymère à base de méthacrylamide-bisacrylamide
fonctionnalisé avec des groupes époxy, ou un polymère de polyméthacrylate fonctionnalisé
avec des groupes époxy.
9. Biocatalyseur selon les revendications 1 à 8, caractérisé en ce que les enzymes UdP et PNP sont d'origine procaryote.
10. Biocatalyseur selon les revendications 1 à 8, caractérisé en ce que les enzymes UdP et PNP sont produites par un procédé de recombinaison.
11. Biocatalyseur selon la revendication 10, caractérisé en ce que les enzymes UdP et PNP sont contenues dans la partie soluble brute extraite à partir
des cellules recombinantes ou dans des préparations partiellement purifiées ou purifiées
dérivant de la partie soluble brute extraite à partir des cellules recombinantes.
12. Utilisation du biocatalyseur selon les revendications 1 à 11, pour la production de
nucléosides par une réaction de transglycosylation enzymatique entre un nucléoside
donneur de sucre et une basse accepteuse de sucre hétérocyclique.
13. Utilisation selon la revendication 12, caractérisée en ce que le sucre du nucléoside donneur est le β-D-ribose, le 2'-désaxy-β-D-ribose, le 2',3'-didésoxy-β-D-ribose,
le β-D-arabinose, l'α-L-xylose, ou leurs dérivés amino ou dérivés halogéno.
14. Utilisation selon la revendication 12, caractérisée en ce que la base du nucléoside donneur est l'uracile.
15. Utilisation selon les revendications 12 à 14, caractérisée en ce que la réaction de transglycosylation est mise en oeuvre en phase aqueuse.
16. Utilisation selon les revendications 12 à 14, caractérisée en ce que la réaction de transglycosylation est mise en oeuvre en présence de tampon phosphate.
17. Utilisation selon les revendications 12 à 14, caractérisée en ce que la réaction de transglycosylation est mise en oeuvre à un pH compris entre 6 et 8,
de préférence entre 6,5 et 7,5.
18. Utilisation selon les revendications 12 à 14, caractérisée en ce que la réaction de transglycosylalion est mise en oeuvre à des températures allant jusqu'à
75°C et de préférence à des températures comprises entre 55 et 60°C.
19. Utilisation selon les revendications 12 à 18, caractérisée en ce qu'une fois la réaction terminée, le catalyseur immobilisé est séparé du mélange réactionnel
par filtration, décantation ou centrifugation, et est réutilisé dans des réactions
de transglycosylation successives.
20. Utilisation selon les revendications 12 à 18, caractérisé en ce que la réaction de transglycosylation est mise en oeuvre dans un système en continu dans
lequel la réaction est achevée par passage au travers du biocatalyseur qui est maintenu
dans une colonne ou dans un réacteur en continu thermostaté.
21. Procédé pour la préparation d'un biocatalyseur selon les revendications 1 à 11, caractérisé en ce que les enzymes uridine phosphorylase et purine nucléoside phosphorylase sont mises en
contact avec la matrice solide, fonctionnalisée avec des groupes époxy, sous agitation,
à un pH compris entre 6 et 9, et à une température comprise entre 10 et 50°C.
22. Procédé selon la revendication 21, caractérisé en ce que les enzymes uridine phosphorylase et purine nucléoside phosphorylase sont mises en
contact séparément avec deux fractions distinctes de la matrice solide, qui sont ensuite
mélangées ensemble pour donner le biocatalyseur.
23. Procédé selon les revendications 21 à 22, caractérisé en ce que les enzymes uridine phosphorylase et purine nucléoside phosphorylase sont utilisées
à des rapports d'activité enzymatique d'uridine phosphorylase/purine nucléoside phosphorylase
compris entre 1/0,5 et 1/3, de préférence à un rapport d'environ 1/1.
24. Procédé selon les revendications 21 à 23, caractérisé en ce que (a) la biomasse obtenue par la fermentation de souches bactériennes exprimant les
enzymes uridine phosphorylase et purine nucléoside phosphorylase sont soumises à une
lyse et centrifugées pour que les fractions solubles brutes soient séparées, (b) le
mélange des fractions solubles brutes ainsi obtenues est mis en contact avec la matrice
solide fonctionnalisée avec des groupes époxy sans autres étapes de purification,
25. Procédé selon la revendication 24, caractérisé en ce qu'une seule souche bactérienne qui exprime simultanément les enzymes uridine phosphorylase
et purine nucléoside phosphorylase est utilisée, ou bien deux souches bactériennes
distinctes, l'une exprimant l'enzyme uridine phosphorylase et l'autre l'enzyme purine
nucléoside phosphorylase, sont utilisées.
26. Procédé selon les revendications 24 à 25, caractérisé en ce que les souches bactériennes sont recombinantes.
27. Procédé selon les revendications 24 à 26, caractérisé en ce qu'avant l'étape (a), la biomasse est soumise à un traitement thermique à une température
de 50 à 70°C, de préférence à 60°C.
28. Procédé selon la revendication 27, caractérisé en ce que le traitement thermique est effectué pendant 20 à 40 minutes, de préférence pendant
30 minutes.
29. Biocatalyseur pouvant être produit par le procédé selon les revendications 21 à 28.
REFERENCES CITED IN THE DESCRIPTION
This list of references cited by the applicant is for the reader's convenience only.
It does not form part of the European patent document. Even though great care has
been taken in compiling the references, errors or omissions cannot be excluded and
the EPO disclaims all liability in this regard.
Patent documents cited in the description
Non-patent literature cited in the description
- OTTO J.L.WERKMAN C.H.Coupled nucleoside phosphorylase reactions in Escherichia coli.Arch. Biochem. Biophys.,
1957, vol. 69, 264-276 [0004]
- DOSKOCIL J.HOLY A.Specificity of purine nucleoside phosphorylase from Escherichia coli.Collect. Czech.
Chem. Commun., 1977, vol. 42, 370-382 [0004]
- UTAGAWA T. et al.Mechanism of purine arabinoside synthesis by bacterial transarabinosylation reactions.,
1985, vol. 49, 82425-2430 [0004]
- HUTCHINSON D.W.New approaches to the synthesis of antiviral nucleosides.Trends Biotechnol., 1990,
vol. 8, 348-353 [0005]
- HANRAHAN J.R.HUTCHINSON D.W.The enzymatic synthesis of antiviral agents.J.Biotechnol., 1992, vol. 23, 193-2120 [0005]
- MAO C. et al.The crystal structure of E.coli purine nucleoside phosphorylase. A comparison with
the human enzyme reveals a conserved topology.Structure, 1997, vol. 5, 1373-1383 [0006]
- BROWSKA A. et al.Properties of purine nucleoside phosphorylase of mammalian and bacterial origin.Z.Naturforsch.,
1989, vol. 45c, 59-70 [0006]
- KRENITSKY T.A. et al.Enzymatic synthesis of purine arabinonucleosides., [0007]
- KRENITSKY T.A. et al.Purine nucleoside synthesis, an efficient method employing nucleoside phosphorylase.Biochemistry,
1981, vol. 20, 3615-3621 [0007]
- KRENITSKI T.A. et al.An enzymic synthesis of purine D-arabinonucleosides.Carbohydrate Res., 1981, vol.
97, 139-146 [0007]
- KRENITSKY T.A. et al.Imidazo [4,5-c] pyridines (3-deaza purines) and their nucleosides as immunosuppressive
and 'anti-inflammatory agents.J.Med.Chem., 1986, vol. 29, 138-143 [0007]
- UTAGAWA et al.Properties of nucleoside phosphorylase from Enterobacter aerogenes.Agric.Biol.Chem.,
1985, vol. 49, 3239-3246 [0010]
- UTAGAWA T.Enzymatic preparation of nucleoside antibiotics.J.Molec.Catalysis B: Enzymatic, 1999,
vol. 6, 3-4215-222 [0010]
- COTTICELLI G. et al.Production of nucleosides by large-scale bioconversion.Nucleosides Nucleotides, 1999,
vol. 18, 4-51135-1136 [0010]
- YOKOZEKI KTSUJI TA novel enzymatic method for the production of purine-2'-deoxynucleosides.J. Molec.
Catalysis B: Enzymatic,, 2000, vol. 10, 207-213 [0011]
- ZINCHENKO A.I. et al.Synthesis of 9-(β-D-arabinofuranosyl) guanine using whole cells of Escherichia coli.Appl.
Microbiol. Biotechnol., 1990, vol. 32, 658-661 [0012]
- BARAI V.N. et al.A universal biocatalyst for the preparation of base- and sugar-modified nucleosides
via an enzymatic transglycosylation.Helv.Chim.Acta, 2002, vol. 85, 1901-1907 [0012]
- VOTRUBA I. et al.Synthesis of 2-deoxy-β-D-ribonucleosides and 2-3-dideoxy-β-D-pentofuranosides on immobilized
bacterial cells.Collect.Czech.Chem.Commun, 1994, vol. 59, 2302-2330 [0012]
- YOKOZEKI K. et al.Production of adenine arabinoside by gel-entrapped cells of Enterobacter aerogenes
in water-organic cosolvent system.Eur. J. Appl. Microbiol. Biotechnol., 1982, vol.
14, 225-231 [0012]
- BESTETTI G. et al.Recombinant bacterial strains for the production of natural nucleosides and modified
analogues thereof., [0013]
- ESIPOV R.S. et al.Overexpression of Escherichia coli genes encoding nucleoside phosphorylases in the
pET/B121 (DE3) system yields active recombinant enzymes.Protein Express. Purif., 2002,
vol. 24, 56-60 [0013]
- SPOLDI E. et al.Recombinant bacterial cells as efficient biocatalysts for the production of nucleosides.Nucleosides
Nucleotides, 2001, vol. 20, 4-7977-979 [0013]
- PUGMIRE M.J.EALICK S.E.Structural analyses reveal two distinct families of nucleoside phosphorylase.Biochem.J.,
2002, vol. 361, [0014]
- a cura diBAILEY J.E.OLLIS D.F.Biochemical engineering fundamentalsMcGraw-Hill19860000157- [0014]
- AVERETT D.R. et al.6-Methoxypurine arabinoside as a selective and potent inhibitor of varicella-zoster
virus.Antimicrob. Agents Chemother., 1991, vol. 35, 5851-857 [0015]
- MAHMOUDIAN M.Biocatalytic production of chiral pharmaceutical intermediates.Biocatalysis Biotransform.,
2000, vol. 18, 105-118 [0015]